Clinical Trial Update: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SPH5030 tablets for HER2-positive/mutated biliary tract cancer or colorectal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Colorectal Cancer

Drugs mentioned

• SPH5030

Snippet

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Conditions: Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | Phase 2 | Status: RECRUITING